The Experts below are selected from a list of 10827 Experts worldwide ranked by ideXlab platform
Dmitri Sviridov - One of the best experts on this subject based on the ideXlab platform.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
Michael Ditiatkovski - One of the best experts on this subject based on the ideXlab platform.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
Alan T Remaley - One of the best experts on this subject based on the ideXlab platform.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
Judy B De Haan - One of the best experts on this subject based on the ideXlab platform.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
Jaye Chindusting - One of the best experts on this subject based on the ideXlab platform.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
-
an apolipoprotein a i mimetic peptide designed with a Reductionist Approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
PLOS ONE, 2013Co-Authors: Michael Ditiatkovski, Wilissa Dsouza, Rajitha Kesani, Jaye Chindusting, Judy B De Haan, Alan T Remaley, Dmitri SviridovAbstract:Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic Approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a Reductionist Approach and has shown exceptional activity in supporting cholesterol efflux but modest anti-inflammatory and anti-oxidant properties in vitro. In this study we compared these in vitro properties with the capacity of this peptide to modify rates of reverse cholesterol transport and development of atherosclerosis in mouse models. The peptide enhanced the rate of reverse cholesterol transport in C57BL/6 mice and reduced atherosclerosis in Apoe−/− mice receiving a high fat diet. The peptide modestly reduced the size of the plaques in aortic arch, but was highly active in reducing vascular inflammation and oxidation. Administration of the peptide to Apoe−/− mice on a high fat diet reduced the levels of total, high density lipoprotein and non-high density lipoprotein cholesterol and triglycerides. It increased the proportion of smaller HDL particles in plasma at the expense of larger HDL particles, and increased the capacity of the plasma to support cholesterol efflux. Thus, ELK-2A2K2E peptide reduced atherosclerosis in Apoe−/− mice, however, the functional activity profile after chronic in vivo administration was different from that found in acute in vitro studies.
